Metformin, a first-line T2DM treatment, affects the gastrointestinal tract by altering glucose uptake, GLP-1 secretion, gut microbiota, and immune response [33, 34], but it rarely causes bowel obstruction. This evidence concerns the gene GCG and intestinal obstruction.